Abbott TactiFlex Duo keeps 92.6% of AFib patients free of documented recurrence in standard monitoring
Abbott’s investigational TactiFlex Duo dual-energy ablation catheter delivered favorable 12-month results in the FlexPulse Global IDE study, supporting the company’s effort to secure U.S. FDA approval after receiving CE Mark in Europe.